Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
ResMed (NYSE: RMD) reported a strong fourth quarter for fiscal 2021, with revenue rising 14% to $876.1 million. Operating profit increased 8%, while non-GAAP operating profit rose 7%. Full-year revenue also grew 8% to $3.2 billion, with non-GAAP diluted EPS at $5.33. The gross margin contracted, mainly due to a shift in product mix. An 8% dividend increase to $0.42 per share was announced. CEO Mick Farrell highlighted recovery in core sleep apnea and COPD patient flow despite challenges from prior COVID-19 ventilator sales. A virtual Investor Day is scheduled for September 8, 2021.
ResMed (NYSE: RMD) will release its fourth quarter fiscal year 2021 financial results on August 5, 2021, after NYSE closure. A webcast to discuss these results will follow, providing essential insights into the company's performance and future outlook. The event starts at 1:30 p.m. PDT / 4:30 p.m. EDT. Interested parties can access the details via ResMed's investor page. A replay will be available shortly after the session, continuing until August 19, 2021.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. EDT. The chat will be available via a live video webcast, with a replay accessible approximately 12 hours after the event, remaining available until June 8, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve quality of life and lower healthcare costs globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 1:20 p.m. CDT. The event will be accessible via video webcast, with a replay available approximately 24 hours after the event and lasting until July 1, 2021. ResMed focuses on innovative solutions for chronic diseases, helping improve patient quality of life and reduce healthcare costs worldwide.
ResMed (NYSE: RMD) reported its third-quarter fiscal 2021 results, revealing a 3% year-over-year increase in net operating profit but a non-GAAP revenue drop to $768.8 million, down 3% on a constant currency basis. The GAAP diluted EPS was $(0.54), compared to $1.12 last year, primarily due to a $255 million reserve related to tax disputes. Non-GAAP diluted EPS rose by 1% to $1.30. Additionally, operational cash flow was $196.3 million, and a quarterly cash dividend of $0.39 per share was declared.
ResMed (NYSE: RMD) announced that CFO Brett Sandercock will present virtually at the Macquarie Australia Conference on May 5, 2021, at 8:45 a.m. AEST. This event will be accessible via video webcast, with a replay available for Macquarie clients 24 hours post-event until May 26, 2021. ResMed is known for its innovative digital health technologies and cloud-connected devices aimed at improving care for chronic diseases like sleep apnea and COPD, effectively transforming healthcare delivery worldwide.
ResMed plans to release its third-quarter fiscal year 2021 financial results on April 29, 2021, post-market closure. The earnings call will be hosted by management at 1:30 p.m. PDT (4:30 p.m. EDT) with an international audience included. A webcast link for the earnings results is provided for stakeholders. A replay of the webcast will be available shortly after, with a phone replay accessible until May 13, 2021. ResMed is committed to providing innovative healthcare solutions for chronic diseases worldwide, with operations in over 140 countries.
ResMed (NYSE: RMD) has announced that Rob Douglas, president and COO, and Brett Sandercock, CFO, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2021, at 4:15 p.m. EDT. The event will be accessible via a video webcast. A replay will be available one hour post-event until June 21, 2021. ResMed focuses on innovative solutions to treat chronic diseases, providing digital health technologies and cloud-connected medical devices that enhance the quality of life for patients globally.
Summary not available.
MatrixCare announced that its Home Health and Hospice EHR solution has been awarded Best in KLAS for Home Health EHR (Large) for the second consecutive year. The solution achieved a Home Health score of 88.3, up from 87.1 last year, leading competitors by 2 points. In the Hospice category, MatrixCare leads by 13.2 points, to be recognized in next year's awards. The company focuses on innovation and customer support, especially during the pandemic, and will be acknowledged in a virtual awards ceremony on February 23.